Real-world Safety and Efficacy of Indacaterol/Glycopyrronium in Japanese Patients with Chronic Obstructive Pulmonary Disease: A 52-week Post-marketing Surveillance-Reference-Cited by-同舟云学术

Real-world Safety and Efficacy of Indacaterol/Glycopyrronium in Japanese Patients with Chronic Obstructive Pulmonary Disease: A 52-week Post-marketing Surveillance

Published:2021 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Kato Chihiro¹,Yoshisue Hajime¹,Nakamura Noriko¹,Sasajima Takayoshi¹

Affiliation:

1. Novartis Pharma K.K, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7845-21/_pdf

Reference29 articles.

1. 1. Global Initiative for Chronic Obstructive Lung Disease; Global Strategy for the Diagnosis, Management and Prevention of COPD. Available from [Internet]. Available from: http://www.goldcopd.org/.

2. 2. WHO Chronic Respiratory Diseases Fact Page. Available from [Internet]. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)

3. 3. WHO Chronic Respiratory Diseases Fact Page. Available from [Internet]. Available from: https://www.who.int/respiratory/copd/burden/en/.

4. 4. Fukuchi Y, Nishimura M, Ichinose M, et al. COPD in Japan: the Nippon COPD Epidemiology study. Respirology 9: 458-465, 2004.

5. 5. Minakata Y, Ichinose M. Epidemiology of COPD in Japan. Nihon rinsho Japanese journal of clinical medicine 69: 1721-1726, 2011.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhaled therapy, cardiovascular risk and benefit–risk considerations in COPD: innocent until proven guilty, orvice versa?;European Respiratory Journal;2023-02